CASI Pharmaceuticals Inc (NASDAQ:CASI)

1.40
Delayed Data
As of May 22
 -0.0138 / -0.98%
Today’s Change
1.07
Today|||52-Week Range
2.09
+5.26%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$45.9M

Company Description

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market. The Company operates through one business segment, which is the development of targeted therapeutics primarily for the treatment of cancer. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. The drugs are Captisol-Enabled, ZEVALIN and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.

Contact Information

CASI Pharmaceuticals, Inc.
9620 Medical Center Drive
Rockville Maryland 20850
P:(240) 864-2600
Investor Relations:

Employees

Shareholders

Other institutional7.01%
Mutual fund holders1.56%
Individual stakeholders1.44%

Top Executives

Ken Keyong RenChief Executive Officer & Director
Cynthia Wong HuCOO, Secretary, Vice President & General Counsel
Sara B. CapitelliChief Accounting Officer & Vice President-Finance
Rong ChenChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account